diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM2014121-28diaendo-6326Research ArticleВопросы патогенезаPathogenesisГормонально-метаболические и генетические маркеры чувствительности к метформину при диабете и раке: предсказание и реальностьHormonal, metabolic and genetic predictors of metformin efficacy in patients with diabetes mellitus and cancerБерштейнЛев МихайловичBershteynLev Mikhaylovich

Доктор медицинских наук, профессор, руководитель лаборатории онкоэндокринологии

MD, PhD, Professor, Head of the Onco-endocrinology laboratory

levmb@endocrin.spb.ruВасильевДмитрий АлексеевичVasil'evDmitriy Alexeevich

Кандидат медицинских наук, старший научный сотрудник лаборатории онкоэндокринологии

MD, PhD, Senior Researcher, Onco-endocrinology laboratory

dvasilyev@hotmail.comИевлеваАглая ГеннадиевнаIevlevaAglaya Gennadievna

Кандидат медицинских наук, научный сотрудник лаборатории молекулярной онкологии

MD, PhD, Researcher, Onco-endocrinology laboratory

aglayai@inbox.ruПорошинаТатьяна ЕвгеньевнаPoroshinaTatiana Evgen'evna

Врач клинико-лабораторной  диагностики лаборатории эндокринологии

MD, PhD, Phisician in Onco-endocrinology laboratory

levmb@endocrin.spb.ruИмянитовЕвгений НаумовичImyanitovEvgeny Naumovich

Доктор медицинских наук, профессор, руководитель отдела биологии опухолевого роста

MD, PhD, Professor, Head of the Cancer growth department

evgeny@imyanitov.spb.ruФГБУ «Научно-исследовательский институт онкологии им. Н.Н. Петрова»РоссияPetrov Research Institute of OncologyRussian Federation2014290320141712014 №12128Copyright © Берштейн Л.М., Васильев Д.А., Иевлева А.Г., Порошина Т.Е., Имянитов Е.Н., 20142014Берштейн Л.М., Васильев Д.А., Иевлева А.Г., Порошина Т.Е., Имянитов Е.Н.Bershteyn L.M., Vasil'ev D.A., Ievleva A.G., Poroshina T.E., Imyanitov E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/6326метформинчувствительность к терапиисахарный диабет 2 типаонкопатологияинсулинорезистентностьэстрадиолгенетические полиморфизмыmetforminefficacytype 2 diabetes mellituscancerinsulin resistanceestradiolsingle nucleotide polymorphismsReferences1. The Use of Medicines in the United States: Review of 2012. IMS Institute for Healthcare Informatics. May 2013, 50 pp. http://www.imshealth.com1. The Use of Medicines in the United States: Review of 2012. IMS Institute for Healthcare Informatics. May 2013, 50 pp. http://www.imshealth.comEvans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005 апр.;330(7503):1304-1305. Available from: http://europepmc.org/abstract/MED/15849206 PubMed PMID: 15849206. doi: 10.1136/bmj.38415.708634.F7.Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005 апр.;330(7503):1304-1305. Available from: http://europepmc.org/abstract/MED/15849206 PubMed PMID: 15849206. doi: 10.1136/bmj.38415.708634.F7.Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, et al. Metformin: multi-faceted protection against cancer.. Oncotarget 2011 дек.;2(12):896-917. Available from: http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=387 PubMed PMID: 22203527.Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, et al. Metformin: multi-faceted protection against cancer.. Oncotarget 2011 дек.;2(12):896-917. Available from: http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=387 PubMed PMID: 22203527.Шестакова М. В., Зилов А. В. Выбор оптимальной сахароснижающей терапии у пациентов с сахарным диабетом в дебюте заболевания. Consilium medicum. 2010; 12(12): 5–10 [Shestakova M.V., Zilov A.V. Vybor sacharosnizhajuschej terapii u pazientov s saharnym diabetom v debjute zabolevanija].Шестакова М. В., Зилов А. В. Выбор оптимальной сахароснижающей терапии у пациентов с сахарным диабетом в дебюте заболевания. Consilium medicum. 2010; 12(12): 5–10 [Shestakova M.V., Zilov A.V. Vybor sacharosnizhajuschej terapii u pazientov s saharnym diabetom v debjute zabolevanija].Берштейн Л.М. Диабет, ожирение и онкологическая заболеваемость: риски и антириски. Diabetes mellitus. 2012;(4):81–88 [Lev M. Berstein Diabet, ozhirenie I onkologicheskaya zabolevaemostj: riski i antiriski].Берштейн Л.М. Диабет, ожирение и онкологическая заболеваемость: риски и антириски. Diabetes mellitus. 2012;(4):81–88 [Lev M. Berstein Diabet, ozhirenie I onkologicheskaya zabolevaemostj: riski i antiriski].Scheen AJ, Lefebvre PJ. Oral antidiabetic agents. A guide to selection. Drugs 1998;55(2):225-236. Available from: http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+1115-70-4 PubMed PMID: 9506242. doi: org/10.2165/00003495-199855020-00004.Scheen AJ, Lefebvre PJ. Oral antidiabetic agents. A guide to selection. Drugs 1998;55(2):225-236. Available from: http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+1115-70-4 PubMed PMID: 9506242. doi: org/10.2165/00003495-199855020-00004.Ong CR, Molyneaux LM, Constantino MI, Twigg SM, Yue DK. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care 2006;29(11):2361-2364. Available from: http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+1115-70-4 PubMed PMID: 17065668. doi: org/10.2337/dc06-0827.Ong CR, Molyneaux LM, Constantino MI, Twigg SM, Yue DK. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care 2006;29(11):2361-2364. Available from: http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+1115-70-4 PubMed PMID: 17065668. doi: org/10.2337/dc06-0827.Christensen MMH, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 2011;21(12):837-850. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=01213011-201112000-00008 PubMed PMID: 21989078. doi: 10.1097/FPC.0b013e32834c0010.Christensen MMH, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 2011;21(12):837-850. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=01213011-201112000-00008 PubMed PMID: 21989078. doi: 10.1097/FPC.0b013e32834c0010.Berstein LM, Iyevleva AG, Vasilyev D, Poroshina TE, Imyanitov EN. Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer. Cell Cycle 2013 окт.;12(23):3681-3688. Available from: http://antibodies.cancer.gov/apps/site/detail/CPTC-OTUB1-1#CPTC-OTUB1-1 PubMed PMID: 24145224. doi: 10.4161/cc.26868.Berstein LM, Iyevleva AG, Vasilyev D, Poroshina TE, Imyanitov EN. Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer. Cell Cycle 2013 окт.;12(23):3681-3688. Available from: http://antibodies.cancer.gov/apps/site/detail/CPTC-OTUB1-1#CPTC-OTUB1-1 PubMed PMID: 24145224. doi: 10.4161/cc.26868.Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 2012;30(21):2593-2600. Available from: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2011.39.3769 doi: 10.1200/JCO.2011.39.3769.Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 2012;30(21):2593-2600. Available from: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2011.39.3769 doi: 10.1200/JCO.2011.39.3769.Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab 2008;93(3):792-800. Available from: http://europepmc.org/abstract/MED/18000088 PubMed PMID: 18000088. doi: 10.1210/jc.2007-1736.Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab 2008;93(3):792-800. Available from: http://europepmc.org/abstract/MED/18000088 PubMed PMID: 18000088. doi: 10.1210/jc.2007-1736.GoDARTS , Diabetes U. Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2, Zhou K, Bellenguez C,Spencer CC, et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011;2011(43):117-120. Available from: http://europepmc.org/abstract/MED/21186350 PubMed PMID: 21186350. doi: 10.1038/ng.735.GoDARTS , Diabetes U. Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2, Zhou K, Bellenguez C,Spencer CC, et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011;2011(43):117-120. Available from: http://europepmc.org/abstract/MED/21186350 PubMed PMID: 21186350. doi: 10.1038/ng.735.Thameem F, Puppala S, Lehman DM, Stern MP, Blangero J, Abboud HE, et al. The Ser(326)Cys Polymorphism of 8-Oxoguanine Glycosylase 1 (OGG1) Is Associated with Type 2 Diabetes in Mexican Americans. Hum Hered 2010;70(2):97-101. Available from: http://europepmc.org/abstract/MED/20606456 PubMed PMID: 20606456. doi: 10.1159/000291964.Thameem F, Puppala S, Lehman DM, Stern MP, Blangero J, Abboud HE, et al. The Ser(326)Cys Polymorphism of 8-Oxoguanine Glycosylase 1 (OGG1) Is Associated with Type 2 Diabetes in Mexican Americans. Hum Hered 2010;70(2):97-101. Available from: http://europepmc.org/abstract/MED/20606456 PubMed PMID: 20606456. doi: 10.1159/000291964.YuM U, Imyanitov EN, Vasilyev DA, Berstein LM. Polymorphic Markers Associated with Genes Responsible for Lipid and Carbohydrate Metabolism Disorders and Insulin Resistance in Cancer Patients. Molecular Biology (Mosk 2008;42(6):843-851. Available from: http://link.springer.com/10.1134/S0026893308060034 doi: 10.1134/S0026893308060034.YuM U, Imyanitov EN, Vasilyev DA, Berstein LM. Polymorphic Markers Associated with Genes Responsible for Lipid and Carbohydrate Metabolism Disorders and Insulin Resistance in Cancer Patients. Molecular Biology (Mosk 2008;42(6):843-851. Available from: http://link.springer.com/10.1134/S0026893308060034 doi: 10.1134/S0026893308060034.Le TN, Nestler JE, Strauss 3rd JF, Wickham 3rd EP. Sex hormone-binding globulin and type 2 diabetes mellitus. Trends Endocrinol Metab 2012;23(1):32-40. Available from: http://europepmc.org/abstract/MED/22047952 PubMed PMID: 22047952. doi: 10.1016/j.tem.2011.09.005.Le TN, Nestler JE, Strauss 3rd JF, Wickham 3rd EP. Sex hormone-binding globulin and type 2 diabetes mellitus. Trends Endocrinol Metab 2012;23(1):32-40. Available from: http://europepmc.org/abstract/MED/22047952 PubMed PMID: 22047952. doi: 10.1016/j.tem.2011.09.005.Avery CL, He Q, North KE, Ambite JL, Boerwinkle E, Fornage M, et al. A phenomics-based strategy identifies loci on APOC1, BRAP, and PLCG1 associated with metabolic syndrome phenotype domains. PLoS Genet 2011;7(10). Available from: http://dx.plos.org/10.1371/journal.pgen.1002322 PubMed PMID: 22022282. doi: 10.1371/journal.pgen.1002322..Avery CL, He Q, North KE, Ambite JL, Boerwinkle E, Fornage M, et al. A phenomics-based strategy identifies loci on APOC1, BRAP, and PLCG1 associated with metabolic syndrome phenotype domains. PLoS Genet 2011;7(10). Available from: http://dx.plos.org/10.1371/journal.pgen.1002322 PubMed PMID: 22022282. doi: 10.1371/journal.pgen.1002322..Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res 2011;13(6):223-225. Available from: http://breast-cancer-research.com/content/13/6/223 PubMed PMID: 22114898. doi: 10.1186/bcr2942.Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res 2011;13(6):223-225. Available from: http://breast-cancer-research.com/content/13/6/223 PubMed PMID: 22114898. doi: 10.1186/bcr2942.Берштейн ЛМ, Васильев ДА, Коваленко ИГ, Порошина ТЕ, Кисельников КС, Бояркина МП и соавт. Влияние метформина и N-ацетилцистеина на маммографическую плотность молочных желез у женщин постменопаузального возраста. Вопросы онколщгии. 2012; (58):45-49 [Bershteĭn LM, Vasil'ev DA, Kovalenko IG, Poroshina TE, Kisel'nikov KS, Boiarkina MP, et al. Vlijanie metformina i N-acetilcisteina na mammographicheskuju plotnostj molochnyh zhelez u zhenschin postmenopausaljnogo vozrasta. Questions of Oncology. 2012;(58):45-49]. PubMed PMID: 22629827.Берштейн ЛМ, Васильев ДА, Коваленко ИГ, Порошина ТЕ, Кисельников КС, Бояркина МП и соавт. Влияние метформина и N-ацетилцистеина на маммографическую плотность молочных желез у женщин постменопаузального возраста. Вопросы онколщгии. 2012; (58):45-49 [Bershteĭn LM, Vasil'ev DA, Kovalenko IG, Poroshina TE, Kisel'nikov KS, Boiarkina MP, et al. Vlijanie metformina i N-acetilcisteina na mammographicheskuju plotnostj molochnyh zhelez u zhenschin postmenopausaljnogo vozrasta. Questions of Oncology. 2012;(58):45-49]. PubMed PMID: 22629827.Берштейн ЛМ, Максимов СЯ, Данилова МА, Гершфельд ЭД, Бояркина МП, Хаджимба АС и соавт. Сравнение эффектов ингибиторов ароматазы и метформина при их неоадъювантном применении у больных раком эндометрия. Вопросы онкологии. 2011; (57):737-741. [Bershteyn LM, Maksimova SYa , Danilova MA, Gershfel'd ED, Boyarkina MP, Khadzhimba AS. Sravnenie effektov ingibitorov aromatazi i metformina pri ih neoadjuvantnom primenenii u boljnyh rakom endometrija. Questions of Oncology 2011;(57):737-741]. PubMed PMID: 22416390.Берштейн ЛМ, Максимов СЯ, Данилова МА, Гершфельд ЭД, Бояркина МП, Хаджимба АС и соавт. Сравнение эффектов ингибиторов ароматазы и метформина при их неоадъювантном применении у больных раком эндометрия. Вопросы онкологии. 2011; (57):737-741. [Bershteyn LM, Maksimova SYa , Danilova MA, Gershfel'd ED, Boyarkina MP, Khadzhimba AS. Sravnenie effektov ingibitorov aromatazi i metformina pri ih neoadjuvantnom primenenii u boljnyh rakom endometrija. Questions of Oncology 2011;(57):737-741]. PubMed PMID: 22416390.Cazzaniga M, DeCensi A, Pruneri G, Puntoni M, Bottiglieri L, Varricchio C. et al. The effect of metformin on apoptosis in a breast cancer presurgical trial. Br. J. Cancer 2013;109(11):2792-2797. Available from: http://www.nature.com/doifinder/10.1038/bjc.2013.657 doi: 10.1038/bjc.2013.657.Cazzaniga M, DeCensi A, Pruneri G, Puntoni M, Bottiglieri L, Varricchio C. et al. The effect of metformin on apoptosis in a breast cancer presurgical trial. Br. J. Cancer 2013;109(11):2792-2797. Available from: http://www.nature.com/doifinder/10.1038/bjc.2013.657 doi: 10.1038/bjc.2013.657.Wahdan-Alaswad R, Fan Z, Edgerton SM, Liu B, Deng XS, Arnadottir SS. et al. Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle 2013;12(24):3759-3769. Available from: http://www.landesbioscience.com/journals/cc/abstract.php?id=26641 PubMed PMID: 24107633. doi: 10.4161/cc.26641.Wahdan-Alaswad R, Fan Z, Edgerton SM, Liu B, Deng XS, Arnadottir SS. et al. Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle 2013;12(24):3759-3769. Available from: http://www.landesbioscience.com/journals/cc/abstract.php?id=26641 PubMed PMID: 24107633. doi: 10.4161/cc.26641.

The authors declare that there are no conflicts of interest present.